Ropeginterferon alfa-2b

 

Category: Biosimilars

Exhibitor: PHARMAESSENTIA CORP.

Booth No: M110

 

Characteristic

 

In the field of protein drug design, the process of pegylation of the therapeutic protein preserves its biologic activity by targeting the PEG polymer (polyethylene glycol) at a specific and a defined region on the protein. PharmaEssentia’s pegylation technology platform is designed to increase the protein drug’s efficacy by prolonging its circulation in the blood stream. PharmaEssentia creates a novel product- Ropeginterferon alfa-2b, it’s a long-acting, mono-pegylated proline interferon with improved pharmacokinetic properties allowing once every two weeks administration offering improved tolerability and convenience. The marketing authorization for Ropeginterferon alfa-2b for the treatment of Polycythemia Vera (PV) is granted by EMA, Taiwan, Korea, US, Japan, Singapore, Malaysia, China, Brazil, Argentina and Hong Kong. Additionally, Ropeginterferon alfa-2b for the treatment of Essential Thrombocythemia (ET) is approved by Taiwan TFDA in May, 2026.

 

 

 

Back